Brazil approves sale of medical cannabis in pharmacies

Medical marijuana
Credit: CC0 Public Domain
Brazil's health watchdog on Tuesday approved the sale of cannabis-based products for medical use in pharmacies to people with a prescription.

The regulation, which takes effect in the coming months, also allows for the manufacture of such products in a laboratory, the Brazilian Health Regulatory Agency (Anvisa) said in a statement.

Anvisa is analyzing the possibility of permitting the cultivation of medical cannabis.

In recent years, several countries in Latin America have legalized cannabis for , including Uruguay, Chile, Colombia, Argentina, Mexico and Peru.

President Jair Bolsonaro has previously expressed support for medical cannabis. But the ultraconservative leader would "not permit loopholes in the law to be used for the planting and consumption of marijuana," his spokesman Otavio Rego Barros told reporters in August.

Since 2015, Anvisa has allowed people with a medical prescription to import cannabidiol, or CBD, a non-psychoactive marijuana derivative, for the treatment of epilepsy and chronic illnesses.

The new regulation allows for the sale of products with a concentration of tetrahydrocannabinol, or THC—the main psychoactive constituent responsible for marijuana's intoxicating effects—of more than 0.2 percent to terminally ill patients or those who have exhausted alternative treatment options.

Others will be allowed to buy products with a THC concentration of less than 0.2 percent.


Explore further

Two firms first to export LatAm medicinal marijuana to Europe

© 2019 AFP

Citation: Brazil approves sale of medical cannabis in pharmacies (2019, December 3) retrieved 11 December 2019 from https://medicalxpress.com/news/2019-12-brazil-sale-medical-cannabis-pharmacies.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments